One Vaccine Dose can be enough for people already having COVID-19 Infection for a small NIH supported study

For the millions of Americans now eligible to receive the Pfizer or Moderna COVID-19 vaccines, it’s recommended that everyone get two shots. The first dose of these mRNA vaccines trains the immune system to recognize and attack the spike protein on the surface of SARS-CoV-2, the virus that causes COVID-19. The second dose, administered a few weeks later, boosts

Read More


Immune system protects children from severe COVID-19

Children are protected from severe COVID-19 because their innate immune system is quick to attack the virus, a new study has found.     The research led by the Murdoch Children’s Research Institute (MCRI) and published in Nature Communications, found that specialised cells in a child’s immune system rapidly target the new coronavirus (SARS-CoV-2).  MCRI’s Dr Melanie Neeland said the

Read More


Report of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021 shows 4,5 cases and 2,5 cases per million doses with Pfizer and Moderna respectively.

The cases of rash on mRNA vaccines are almost non-existent and no deaths have occurred. A research published in the medical journal JAMA, points out that the probability of developing anaphylaxis is only 0.000377%, as out of the approximately 17.5 million vaccinations, no deaths occurred, while only 66 people developed anaphylaxis to mRNA vaccines. A

Read More


Four potential COVID-19 therapeutics enter Phase 2/3 testing in NIH ACTIV-2 trial: between them Camostat mesilate, an orally administered serine protease inhibitor.

Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of promising COVID-19 treatments and vaccines. The new agents entering the randomized, placebo-controlled study are part of ACTIV-2, an adaptive trial designed to

Read More


NIH experts discuss SARS-CoV-2 viral variants: a Dr. Fauci’s paper on JAMA

Editorial emphasizes need for global response. The rise of several significant variants of SARS-CoV-2, the virus that causes COVID-19, has attracted the attention of health and science experts worldwide. In an editorial published today in JAMA: The Journal of the American Medical Association, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the

Read More


IgM have a major role in the neutralizing activity of convalescent plasma against SARSCoV-2

Characterization of the humoral response to SARS-CoV-2, the etiological agent of COVID-19, is essential to help control the infection. The neutralization activity of plasma from COVID-19 patients decreases rapidly during the first weeks after recovery. However, the specific role of each immunoglobulin isotype in the overall neutralizing capacity is still not well understood. In this

Read More


Artificial intelligence yields new ways to combat the coronavirus

Countering COVID-19 mutations and designing updated vaccines could occur at lightning speeds thanks to a new, USC-developed AI framework. USC researchers have developed a new method to counter emergent mutations of the coronavirus and hasten vaccine development to stop the pathogen responsible for killing thousands of people and ruining the economy. Using artificial intelligence (AI),

Read More


A new study on Nature shows that BioNTech/Pfizer vaccine should neutralize SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants.

The Pfizer / BioNTech vaccine is effective against covid-19 variants originating in the UK and South Africa. This is the result of a study published this Monday in Nature Medicine , which showed better results in the first case, the British variant (called B.1.1.7), than in the second, the South African, or B.1.351. The differences, however, are small.

Read More